DXVX announced on the 24th that it has signed a strategic partnership with Dt&CRO to actively pioneer the companion diagnostics market.
The partnership signing ceremony held at Dt&CRO in Yongin was attended by DXVX CEO Kwon Kyu-chan, Head of New Drug Research Division Lee Kyu-hang, and Dt&CRO Chairman Park Chae-kyu and President Choi Soo-young, among others.
Through this strategic partnership, both companies plan to mutually cooperate in discovering client companies requiring companion diagnostics, expanding their hospital and clinic networks, providing cultured cell maintenance and immune cell profiling services, and conducting non-clinical and clinical trials for companion diagnostic development.
Companion diagnostics (CDx) is a diagnostic technique that predicts whether a specific drug will be effective for a patient. Integrating companion diagnostics into new drug development can triple the success rate of new drug development and reduce development costs to one-third.
DXVX will officially launch its companion diagnostics business under the service name ‘CLIDEX™’. CLIDEX is an abbreviation of Cli-D-eX (Clinical data expert program), meaning ‘valuing the increase of clients’ clinical success probability.’ Through companion diagnostic services, it provides methods to identify patients who absolutely need the drug, as well as genome analysis for confirming specific genes during patient selection, immune diagnostics using antibodies, and in vitro diagnostic services. Additionally, it offers methods to develop target biomarkers necessary for patient selection in clinical trials to increase clinical success rates.
Dt&CRO is a domestic full-service CRO providing non-clinical and clinical trials across various fields including pharmaceuticals, medical devices, food, chemicals, and cosmetics. Since its KOSDAQ listing in November 2022, the company has been enhancing its competitiveness. The synergy between the two companies is expected to be high, as Dt&CRO develops biomarkers needed in clinical trials at the preclinical stage.
Representatives from both companies stated, “Through this strategic partnership, we will provide high-quality services to companies requiring companion diagnostic technology and cooperate to reduce the cost and duration of targeted anticancer drug development.”
Meanwhile, besides companion diagnostic services, DXVX also provides genome and immune diagnostic analysis services for maintaining the characteristics of stem cell therapeutics and cancer cell lines or confirming genomic instability, as well as immune cell profiling services through nucleotide sequence analysis of immune cell receptors.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
